Astria Therapeutics
ATXS
ATXS was delisted on the 22nd of January, 2026.
27 hedge funds and large institutions have $37.9M invested in Astria Therapeutics in 2016 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, 10 reducing their positions, and 13 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1.92% less ownership
Funds ownership: 68.49% → 66.58% (-1.9%)
18% less funds holding
Funds holding: 33 → 27 (-6)
28% less capital invested
Capital invested by funds: $52.9M → $37.9M (-$15.1M)
46% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 13
80% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$139K |
| 2 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$107K |
| 3 |
FO
FT Options
Chicago,
Illinois
|
+$75.7K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
+$70.5K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$22.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$489K |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$211K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$172K |
| 4 |
FAM
Fred Alger Management
New York
|
-$141K |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$135K |
ATXS Hedge Fund Activity: Q2 2016 in Review
27 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q2 2016, worth a combined $37.9M — down 28% from $52.9M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of ATXS and 7 opened new positions — a net loss of 6 holders — while 10 trimmed existing stakes and 2 added.
The largest buyer was Bridgeway Capital Management, opening a new position worth an estimated $139K. The largest seller was BlackRock Fund Advisors, cutting an estimated $489K.
- 27 institutional investors held Astria Therapeutics (ATXS) as of Q2 2016, down from 33 in Q1 2016.
- Funds reported $37.9M of Astria Therapeutics stock for Q2 2016, down 28% quarter-over-quarter.
- 7 funds opened new Astria Therapeutics positions in Q2 2016 and 13 closed out, a net change of -6 holders.
- The largest Astria Therapeutics buyer in Q2 2016 was Bridgeway Capital Management, an estimated $139K added.
- The largest Astria Therapeutics seller in Q2 2016 was BlackRock Fund Advisors, an estimated $489K sold.
Based on aggregated 13F filings for Q2 2016.